<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18" class="p">Prostaglandin I2 (PGI
 <sub class="sub">2</sub>) can inhibit platelet aggregation and dilate blood vessels. TXA
 <sub class="sub">2</sub>, a metabolite in arachidonic acid metabolism, possesses activity that is opposite to that of PGI
 <sub class="sub">2</sub>
 <sup class="sup">
  <xref ref-type="bibr" rid="CR20" class="xref">20</xref>
 </sup>. TXA
 <sub class="sub">2</sub> promotes thrombus formation and causes serious injury to renal function
 <sup class="sup">
  <xref ref-type="bibr" rid="CR21" class="xref">21</xref>
 </sup>. Therefore, the PGI
 <sub class="sub">2</sub>/TXA
 <sub class="sub">2</sub> value plays a key role in modulating renal blood flow and function, and is often used as an important indicator of renal injury
 <sup class="sup">
  <xref ref-type="bibr" rid="CR22" class="xref">22</xref>,
  <xref ref-type="bibr" rid="CR23" class="xref">23</xref>
 </sup>. Due to the similar effect with PGI
 <sub class="sub">2</sub>, the PGE
 <sub class="sub">0</sub>/TXA
 <sub class="sub">2</sub> value can be a substitute for the PGI
 <sub class="sub">2</sub>/TXA
 <sub class="sub">2</sub> value. As shown in Fig.Â 
 <xref rid="Fig2" ref-type="fig" class="xref">2b</xref>, the PGE
 <sub class="sub">0</sub>/TXA
 <sub class="sub">2</sub> value in the SPF group was higher than that in the PF group, suggesting that the toxic side effect of PF on the renal system could be alleviated by salt-processing.
</p>
